RESHAW was designed to investigate the impact of Evolva’s Veri-te resveratrol supplementation on cognitive performance, along with a wide range of secondary outcomes, including body composition and perceptions of wellbeing, physical function, and pain.
The crossover trial randomized 125 volunteers to take two capsules containing 75mg of Veri-te daily or a matching placebo supplement for 12 months, followed by the alternate treatment for a further 12 months.
Related: Study: Resveratrol Displays Anti-Stress Effects OptiMSM Reduces Visual Signs of Aging, Study Finds Smart Supplements For: Sharper, Calmer, Happier
Dr. Rachel Wong, one of the lead researchers, summed up the results in the release: “Our observed improvement in overall cognitive performance with resveratrol could potentially reverse cognitive aging by up to 10 years,” specifically in postmenopausal women. She continued: “We observed an improvement in overall cognitive performance, which appeared to be due to improvements in processing speed and cognitive flexibility, which are critical to supporting executive function in the aging population.” Dr. Wong is a Dementia Research Fellow at the National Health and Medical Research Council and the Australian Research Council, a supporter of the study.Clare Panchoo, VP, Health Ingredients, Evolva, added: “This momentous publication from the team at the University of Newcastle highlights the benefits that Veri-te resveratrol can have on brain health, making resveratrol an essential ingredient for postmenopausal women and healthy aging. This first peer-reviewed publication from the RESHAW clinical study provides the evidence that supplementation with Veri-te resveratrol should be a key strategy for the design and delivery of effective supplements that may attenuate the decline in brain health as women age and improve overall wellbeing post-menopause.”
